Precision BioSciences (DTIL) announced the activation of its first U.S. clinical trial site to evaluate PBGENE-HBV as part of the ELIMINATE-B Phase 1 clinical trial. The newly activated site at Massachusetts General Hospital in Boston, Massachusetts, is now actively recruiting patients.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DTIL:
- Precision BioSciences announces presentation at WMS on PBGENE-DMD
- Precision BioSciences announces in vivo gene editing program patent from USPTO
- Precision BioSciences Updates Executive Employment Agreements
- Precision BioSciences: Promising Clinical Milestones and Strategic Advancements Drive Buy Rating
- Precision BioSciences Reports Significant Quarterly Loss